Skip to main content
. 2019 Jan 31;2019(1):CD009075. doi: 10.1002/14651858.CD009075.pub3

Persoon 2017.

Methods Randomisation
  • Single‐blind randomised controlled trial

  • 2 arms: high intensity resistance und interval training for 18 weeks versus standard care


Recruitment period
  • March 2011 to February 2014


Median follow‐up time
  • 12 month follow‐up

Participants Eligibility criteria
  • Diagnosed with multiple myeloma in first line or with HL/NHL in first relapse and treated with HDC and ASCT 6 ‐ 12 weeks ago

  • Sufficiently recovered from the ASCT: Hb > 6.5 mmol/L, WBC > 3.0 × 109/L, platelets > 100 × 109/L

  • Aged 18 to 65 years

  • Able to cycle on a bicycle ergometer with a load of at least 25 Watt

  • Able to walk at least 100 metres independently without crutches/cane(s) or walking frame

  • Give written informed consent


Participants (N = 109)
  • Intervention group (N = 54)

  • Control group (N = 55)


Mean age
  • Interventions group: 53.5

  • Control group: 56


Stage of disease
  • Intervention group: not reported

  • Control group: not reported


Country
  • the Netherlands

Interventions Exercise group
  • 18‐week exercise programme consisting of high‐intensity resistance and interval training. Participants will train on specialised resistance training equipment and bicycle ergometers. In weeks 1 ‐ 12, participants will perform resistance and interval training twice a week for 60 minutes per training session. In weeks 13 ‐ 18 the intensity of exercise will be decreased to 1 session a week with a duration of 60 minutes.


Control group
  • No exercise intervention

Outcomes Reported
  • Physical performance

  • Fatigue

  • Anthropometric measurements

  • Quality of life

  • Adverse events


Not reported but relevant
  • Overall survival


Reported but not relevant
  • Neuropathy objective and self‐reported physical activity level Mood disturbance

  • Functioning in daily life

  • Return to work

  • Cost from a social perspective

  • Bone mineral density


Primary outcome
  • Cardiorespiratory fitness, muscle strength and fatigue

Notes This study was supported by the Alpe d’HuZes/KWF Fund. The authors declare that no competing interests exist
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Quote: "Randomization was concealed, took place after completion of baseline assessments (T0) and was performed by an independent data manager using a validated software program."
Allocation concealment (selection bias) Low risk Quote: "...proceeded using block randomization with block sizes varying randomly between 2, 4 and 6."
Blinding of participants and personnel (performance bias) 
 All outcomes High risk Blinding in this context is not feasible
Blinding of outcome assessor (primary endpoint; mortality) Low risk Outcome not reported. The review authors judge that the outcome mortality in this unblinded trial is unlikely to be influenced by lack of blinding
Blinding of outcome assessor (patient‐reported outcomes) High risk Blinding in this context is not feasible
Blinding of outcome assessor (physical performance, AEs, SAEs) Unclear risk Body composition was assessed by the sports physician and it remains unclear if he was blinded
Incomplete outcome data (attrition bias) 
 All outcomes High risk Quote: "However, we had a relatively high number of missing values"
Selective reporting (reporting bias) Unclear risk Protocol not available
Other bias Low risk This study was supported by the Alpe d’HuZes/KWF Fund. The authors declare that no competing interests exist